<
 
 
 
 
>
hide
You are viewing a Web site, archived on 20:22:58 Oct 30, 2004. It is now a Federal record managed by the National Archives and Records Administration.
External links, forms, and search boxes may not function within this collection.
U.S. Food and Drug Administration
horizonal rule

Congressional Testimony

2000

October

  • Jane E. Henney, M.D., October 3, 2000
    Commissioner of Food and Drug Administration -- Before the Subcommittee on Oversight and Investigations to discuss our efforts to detect and prevent the introduction of counterfeit bulk drugs into the drug supply of the United States (U.S.).
  • Mark A. Elengold, October 3, 2000
    Deputy Director, Operations, Center for Biologics Evaluation and Research (CBER)/FDA -- Before the Committee on Government Reform to discuss the Anthrax Vaccine Adsorbed and the opportunity for FDA to update the Committee of the regulatory status of BioPort Corporation (BioPort), and the Agency's experience with adverse event reports for the anthrax vaccine

September

  • Joseph A Levitt, Esq., September 20, 2000
    Director of the Center for Food Safety and Applied Nutrition/FDA -- Before the Committee on Agriculture, Nutrition, and Forestry, United States Senate to discuss how our food safety system should address microbial contamination.
  • Jane E. Henney, M.D., September 20, 2000
    Commissioner of Food and Drug Administration -- Before the Subcommittee on Labor, Health and Human Services and Education -- Committee of Appropriation to discuss issues related to antimicrobial resistance and FDA's important role in addressing this growing public health problem

July

  • William Egan, Ph.D., July 18, 2000
    Acting Director Office of Vaccine Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), FDA -- Before the Committee on Government Reform to discuss the issue of additives in childhood vaccines, in particular thimerosal.
  • Kathryn C. Zoon, Ph.D., July 12, 2000
    Director Center for Biologics Evaluation and Research, FDA -- Before the Committee on Armed Services to discuss anthrax vaccine and the opportunity for FDA to explain our role in the pre-market review and post-market surveillance of regulated products, and more specifically explain our role with respect to the regulation of the Anthrax Vaccine, Adsorbed.

June

  • David W. Feigal, M.D., June 27, 2000
    Director Center for Devices and Radiological Health, FDA -- Before the Senate Committee on Health, Education, Labor and Pensions to discuss the Agency's approach to the issue of reuse of medical devices labeled for single-use.
  • Linda Suydam, D.P.A., June 14, 2000
    Senior Associate Commissioner, FDA -- Before the Committee on Government Reform to discuss FDA's advisory committees.
  • Dennis E. Baker, June 8, 2000
    Associate Commissioner for Regulatory Affairs, FDA -- Before the Subcommittee on Oversight and Investigations to discuss the concerns about imported counterfeit bulk drugs and the Agency's actions designed to protect the American public from the possible risks that such drugs may pose.
  • Richard Pazdur, M.D., June7, 2000
    Director, Division of Oncology Drug Products, Center for Drug Evaluation and Research (CDER) FDA -- Before the Committee on Government Reform to ensure that new cancer drugs are as safe and effective as possible and to facilitate access to promising therapies for seriously ill and dying patients when no other treatment is available.

May

  • William K. Hubbard, May 25, 2000
    Senior Associate Commisioner for Policy, Planning and Legislation, FDA -- Before the Subcommittee on Oversight and Investigations to discuss FDA's concern about the public health implications of Internet drug sales.
  • William F. Raub, Ph.D., May 25, 2000
    Deputy Assistant Secretary for Science Policy for the Department of Health and Human Services (HHS) -- Before the Subcommittee on Public Health to discuss HHS efforts to protect human research subjects throughout our programs and, in particular, to enhance oversight of human gene transfer research.
  • William F. Raub, Ph.D., May 3, 2000
    Deputy Assistant Secretary for Science Policy for the Department of Health and Human Services (HHS) -- Before the Subcommittee on Criminal Justice to discuss HHS' efforts to protect human research subjects.

March

  • Jane E. Henney, M.D., March 21, 2000
    Commissioner of Food and Drug Administration -- Before the Committee on Health, Education, Labor and Pensions to discuss with you the benefits and risks of pharmaceutical sales over the Internet.
  • Ronald Coene, March 15, 2000
    Deputy Director for Washington Operations, National Center for Toxicological Research (NCTR) -- Subcommittee on National Security to discuss my role with the Ranch Hand Advisory Committee.
  • Jane E. Henney, M.D., March 7, 2000
    Commissioner of Food and Drug Administration -- Before the U.S. Senate -- Committee on Appropriations to discuss the proposed budget for fiscal year 2001.

February

  • Jane E. Henney, M.D., February 29, 2000
    Commissioner of Food and Drug Administration--Before the House Subcommittee to discuss the proposed budget for fiscal year 2001.
  • David Feigal, M.D., February 10, 2000
    Director of the Center for Devices and Radiological Health (CDRH) discuss the Agency's approach to the issue of reuse of medical devices labeled for single-use.
  • Jay P. Siegel, M.D., February 2, 2000
    Director, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration to discuss gene therapy and the Federal government's role in the oversight of this field of medical research.
  • Janet Woodcock, M.D., February 1, 2000
    Director, Center for Drug Evaluation and Research, Food and Drug Administration before the Committee on Health, Education, Labor and Pensions to discussion of drug related adverse events, FDA's role in addressing these events, and what the Agency is doing and can do to reduce their occurrence.

 

Testimony Archive

 

rule link to FDA home page link to U.S. Department of Health and Human Services FDA logo--link to FDA home page